ArticleUnited European gastroenterology journal2017
The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.
Article in United European gastroenterology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers.Clinical pharmacology and therapeutics · 2019Trial
- Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants.Clinical pharmacology in drug development · 2025Article
- HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation.Drug metabolism and disposition: the biological fate of chemicals · 2024Article
- If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs.United European gastroenterology journal · 2021Article
- Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.Gut and liver · 2021Article
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection.Journal of clinical and translational hepatology · 2021Review
- Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.European journal of hospital pharmacy : science and practice · 2021Observational
- Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.International journal of general medicine · 2021Review
- Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.Journal of viral hepatitis · 2020Review
- Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents.Journal of clinical and translational hepatology · 2020Review
- An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease.Clinical liver disease · 2020Review
- Cardiovascular Risk Management and Hepatitis C: Combining Drugs.Clinical pharmacokinetics · 2019Review
- Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir.European journal of drug metabolism and pharmacokinetics · 2018Article
- Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDirect-acting antivirals have improved treatment of chronic hepatitis C virus infection significantly. Direct-acting antivirals inhibit/induce and can also be substrates of drug-metabolising enzymes and transporters. This increases the risk for drug-drug interactions.
objectiveThe purpose of this study was to predict drug-drug interactions with co-medication used by hepatitis C virus-infected patients.
methodsWe assembled a nationwide cohort of hepatitis C patients and collected cross-sectional data on co-medication use. We compiled a list of currently available direct-acting antiviral regimens and cross-checked for potential drug-drug interactions with used co-medication.
resultsThe cohort included 461 patients of which 77% used co-medication. We identified 260 drugs used as co-medication. Antidepressants (7.4%), proton pump inhibitors (7.1%) and benzodiazepines (7.1%) were most frequently used. Of the patients, 60% were at risk for a clinically relevant drug-drug interaction with at least one of the direct-acting antiviral regimens. Interactions were most common with paritaprevir/ritonavir/ombitasvir/dasabuvir and least interactions were predicted with grazoprevir/elbasvir.
conclusionCo-medication use is rich in frequency and diversity in chronic hepatitis C patients. The majority of patients are at risk for drug-drug interactions which may affect efficacy or toxicity of direct-acting antivirals or co-medication. The most recently introduced direct-acting antivirals are associated with a lower risk of drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.